Copyright
©The Author(s) 2017.
World J Gastroenterol. Jan 14, 2017; 23(2): 306-317
Published online Jan 14, 2017. doi: 10.3748/wjg.v23.i2.306
Published online Jan 14, 2017. doi: 10.3748/wjg.v23.i2.306
Table 2 Cumulative number of patients in the per-protocol set with adefovir add-on treatment due to lamivudine antiviral failure at each time point of the trial n (%)
| Week | Vacc. (n = 102) | Ctr. (n = 113) |
| 24 | 1 (0.98) | 0 (0.00) |
| 36 | 2 (1.96) | 1 (0.88) |
| 40 | 4 (3.92) | 5 (4.42) |
| 48 | 7 (6.86) | 8 (7.08) |
| 52 | 11 (10.78) | 14 (12.39) |
| 56 | 17 (16.67) | 18 (15.93) |
| 60 | 27 (26.47) | 26 (23.01) |
| 64 | 34 (33.33) | 32 (28.32) |
- Citation: Yang FQ, Rao GR, Wang GQ, Li YQ, Xie Y, Zhang ZQ, Deng CL, Mao Q, Li J, Zhao W, Wang MR, Han T, Chen SJ, Pan C, Tan DM, Shang J, Zhang MX, Zhang YX, Yang JM, Chen GM. Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy. World J Gastroenterol 2017; 23(2): 306-317
- URL: https://www.wjgnet.com/1007-9327/full/v23/i2/306.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i2.306